XMD 8-92 from Tocris Bioscience, a Bio-Techne Brand

Product Specs
ItemXMD 8-92
CompanyTocris Bioscience, a Bio-Techne Brand
Price $341.00Supplier Page View Company Product Page
Catalog Number4132/10
Quantity10 mg (also 50 mg)
Purity98%
Molecular Weight474.55
Molecule Name2-[[2-Ethoxy-4-(4-hydroxy-1-piperidinyl)phenyl]amino]-5,11-dihydro-5,11-dimethyl-6H-pyrimido[4,5-b][1,4]benzodiazepin-6-one
FormulaC26H30N6O3
StorageStore at RT

Sizes Available: 10 mg (also 50 mg)

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956
Fax: 1 (612) 656-4400

(1) ERK5 modulates IL-6 secretion and contributes to tumor-induced immune suppressionCell death & diseaseOctober 20, 2021Riegel K, Yurugi H, Schlöder J, Jonuleit H, Kaulich M, Kirschner F, Arnold-Schild D, Tenzer S, Schild H, Rajalingam K.

(2) Slug regulates the Dll4-Notch-VEGFR2 axis to control endothelial cell activation and angiogenesisNature communicationsOctober 26, 2020Hultgren NW, Fang JS, Ziegler ME, Ramirez RN, Phan DTT, Hatch MMS, Welch-Reardon KM, Paniagua AE, Kim LS, Shon NN, et al.

(3) MEKK3-MEK5-ERK5 signaling promotes mitochondrial degradationCell death discoveryJanuary 1, 2020Craig JE, Miller JN, Rayavarapu RR, Hong Z, Bulut GB, Zhuang W, Sakurada SM, Temirov J, Low JA, Chen T, et al.

(4) Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine GliomasCancer researchAugust 15, 2019Koncar RF, Dey BR, Stanton AJ, Agrawal N, Wassell ML, McCarl LH, Locke AL, Sanders L, Morozova-Vaske O, Myers MI, et al.

(5) Extracellular signal regulated kinase 5 and inflammasome in progression of mesotheliomaOncotargetJanuary 2, 2018Thompson JK, Shukla A, Leggett AL, Munson PB, Miller JM, MacPherson MB, Beuschel SL, Pass HI, Shukla A.

(7) Aberrant MEK5/ERK5 signalling contributes to human colon cancer progression via NF-κB activationCell death & diseaseApril 9, 2015Simões AE, Pereira DM, Gomes SE, Brito H, Carvalho T, French A, Castro RE, Steer CJ, Thibodeau SN, Rodrigues CM, et al.

(8) Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancerOncotargetMay 30, 2014Al-Ejeh F, Miranda M, Shi W, Simpson PT, Song S, Vargas AC, Saunus JM, Smart CE, Mariasegaram M, Wiegmans AP, et al.

XMD 8-92